Portal de investigación
Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ravandi, Farhad
- Pfeilstoecker, Michael
- Papayannidis, Cristina
- Dombret, Herve
- Lai, Yinzhi
- Petrlik, Erica
- Prebet, Thomas
- Doehner, Hartmut
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 3277-3279
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Ravandi,F,Montesinos,P,Pfeilstoecker,M,Papayannidis,C,Dombret,H,Lai,Y,Petrlik,E et al. Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo. 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2022. New Orleans-LA. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2022 p.p. 3277-3279.